Wells Fargo notes that on Friday afternoon, a jury in St. Louis ordered Abbott to pay $495M in the company’s first necrotizing-entero colitis case, which was higher than the $60M in the first Reckitt NEC case. The firm expects the company to settle these cases for $200M-$300M, which should be quite manageable for Abbott. Wells has an Overweight rating on the shares with a price target of $133.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- Abbott (ABT) Faces $495M Verdict in Infant-Formula Lawsuit
- DexCom downgraded to Neutral from Outperform at Baird
- Stock Market News Today, 7/18/24 – Indices Continue Decline; Jobless Claims Miss Estimates
- Abbott says pipeline continues to be ‘highly productive’
- ABT Earnings: Abbott’s Q3 Earnings Top Street Expectations